|In the field of health, generic competition saves lives. As a medical treatment provider, MSF relies on affordable generic medicines to treat a wide variety of diseases, including tuberculosis, malaria, HIV/AIDS and other infections that afflict the poorest and most vulnerable populations. And we are not alone in this – the major treatment initiatives, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US government’s PEPFAR programme and many others depend heavily on affordable generics.
But the TPP is threatening to cut off the lifeline that generic drugs provide for people living with HIV/AIDS and many other diseases. The availability of generic medicines in a particular country depends on a complex structure of national rules and regulations governing patents and other intellectual property rights. Trade pacts and other international agreements can impact these domestic regulations, and governments have long recognized the need to balance public health interests with intellectual property (IP) demands when negotiating trade agreements. In fact, multiple multilateral commitments have reaffirmed the importance of this balance, including the 2001 WTO Doha Declaration on TRIPS and Public Health and the 2008 WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property. However, despite these commitments, the US government pushed policies in the TPP that represent the most far-reaching attempt to date to impose aggressive IP standards in a trade agreement with developing countries – policies that further tip the balance towards strong IP regimes favoring commercial interests and away from public health. For pharmaceuticals and other health commodities, stronger IP regimes mean extended patent monopolies and delayed generic competition, and that translates into higher prices for people who need medicines. In developing countries, where people rarely have health insurance and must pay for medicines out of pocket, high prices keep lifesaving medicines out of reach and are often a matter of life and death. Billed as a model agreement not just for countries in the Asia-Pacific region, but the world over, the TPP is on track to set a damaging precedent with serious implications for many developing countries where MSF works, and beyond. Governments have a responsibility to ensure that public health interests are not trampled by commercial interests, and must resist pressures to erode hard-fought legal safeguards for public health that represent a lifeline for people in developing countries. MSF urges the U.S. and all other TPP negotiating governments to not ratify the TPP agreement as long as it includes provisions that will harm access to medicines.
|en que nos afectará el tratado transpacífico en el precio de los fármacos, primero está el tema de los bioequivalentes, el último by pass a la problemática de patentes y May 10th Agreement, que buscaba favorecer el acceso a medicamentos baratosal alejar el tiempo de caducidad de las patentes o dicho de otro modo impedir la inscripción de genéricos|